🔴 ProMIS Neurosciences is trading 5% down today on profit-taking following PMN310 clinical data updates

ProMIS Neurosciences is trading at $13.30 (5% down) as investors digest recent clinical updates and engage in profit-taking following a multi-day rally.

• The company reported the first human evidence of amyloid-beta oligomer target engagement for its lead candidate, PMN310, at the AAIC 2026 conference on July 14.
• The recent price action follows news that the company exceeded target enrollment in its PRECISE-AD Phase 1b trial, prompting a pullback after significant recent gains.